Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, Nakasuka T, Watanabe H, Kano H, Nishii K, Makimoto G, Kondo T, Ninomiya K, Fujii M, Kubo T, Ohashi K, Matsuoka KI, Hotta K, Tabata M, Maeda Y, Kiura K. Ando C, et al. Cancer Sci. 2023 Nov;114(11):4343-4354. doi: 10.1111/cas.15958. Epub 2023 Sep 15. Cancer Sci. 2023. PMID: 37715310 Free PMC article.
Multiple Mucosa-associated Lymphoid Tissue Lymphoma of the Trachea.
Minami D, Ando C, Sato K, Moriwaki K, Sugahara F, Nakasuka T, Iwamoto Y, Fujiwara K, Shibayama T, Yonei T, Sato T. Minami D, et al. Among authors: ando c. Intern Med. 2017 Nov 1;56(21):2907-2911. doi: 10.2169/internalmedicine.8269-16. Epub 2017 Sep 25. Intern Med. 2017. PMID: 28943536 Free PMC article.
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H, Ichihara E, Kayatani H, Makimoto G, Ninomiya K, Nishii K, Higo H, Ando C, Okawa S, Nakasuka T, Kano H, Hara N, Hirabae A, Kato Y, Ninomiya T, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Watanabe H, et al. Among authors: ando c. Cancer Sci. 2021 May;112(5):1853-1864. doi: 10.1111/cas.14801. Epub 2021 Mar 18. Cancer Sci. 2021. PMID: 33410241 Free PMC article.
SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer.
Kano H, Ichihara E, Watanabe H, Nishii K, Ando C, Nakasuka T, Ninomiya K, Kato Y, Kubo T, Rai K, Ohashi K, Hotta K, Tabata M, Maeda Y, Kiura K. Kano H, et al. Among authors: ando c. Mol Cancer Ther. 2021 Sep;20(9):1653-1662. doi: 10.1158/1535-7163.MCT-20-0965. Epub 2021 Jun 22. Mol Cancer Ther. 2021. PMID: 34158345 Free article.
First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
Kudo K, Nishii K, Makimoto G, Ishikawa N, Tsubata Y, Kodani M, Fujimoto N, Yamasaki M, Kubota T, Takigawa N, Fujitaka K, Kanaji N, Shibayama T, Itano J, Ando C, Hotta K, Kiura K. Kudo K, et al. Among authors: ando c. J Cancer Res Clin Oncol. 2022 Aug;148(8):1869-1877. doi: 10.1007/s00432-021-03893-z. Epub 2022 Apr 6. J Cancer Res Clin Oncol. 2022. PMID: 35386002
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.
Nishii K, Ohashi K, Tomida S, Nakasuka T, Hirabae A, Okawa S, Nishimura J, Higo H, Watanabe H, Kano H, Ando C, Makimoto G, Ninomiya K, Kato Y, Kubo T, Ichihara E, Hotta K, Tabata M, Toyooka S, Udono H, Maeda Y, Kiura K. Nishii K, et al. Among authors: ando c. Cancer Immunol Res. 2022 Sep 1;10(9):1111-1126. doi: 10.1158/2326-6066.CIR-21-0751. Cancer Immunol Res. 2022. PMID: 35802887 Free article.
79 results